TrialPath
Recruiting

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

NCT07489651 · Reunion Neuroscience Inc
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder
About this study
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Eligibility criteria
Inclusion Criteria: * Has Generalized Anxiety Disorder as defined by DSM-5-TR * If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant. * Is willing and able to comply with the conditions and requirements of the study Exclusion Criteria: * Has a significant risk of suicide * Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder * Has other concurrent psychiatric disorders that is the primary disorder. * Has other medically significant conditions rendering unsuitability for the study * Has used or will need to use prohibited medications or therapies * Has a known sensitivity or intolerance to study intervention or potential rescue medications
Study design
Enrollment target: 64 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2026-04-20
Estimated completion: 2027-04
Last updated: 2026-05-18
Interventions
Drug: RE104 for InjectionDrug: Placebo
Primary outcomes
  • RE104 30 mg versus placebo change from Baseline at Week 4 in Hamilton Anxiety Rating Scale (HAM-A) total score (Week 4)
Sponsor
Reunion Neuroscience Inc · industry
Contacts & investigators
ContactMark Pollack Chief Medical Officer, M.D. · contact · info@reunionneuro.com · 1-888-880-REUN
InvestigatorMark Pollack, M.D. · study_director, Reunion Neuroscience Inc
All locations (12)
Lighthouse PsychiatryRecruiting
Gilbert, Arizona, United States
Open Mind TherapeuticsRecruiting
San Francisco, California, United States
TRIP Clinic at Psychedelic Science InstituteRecruiting
Santa Monica, California, United States
University of South FloridaRecruiting
Tampa, Florida, United States
Atlanta Center for Medical ResearchRecruiting
Atlanta, Georgia, United States
CenExel iResearch, LLCRecruiting
Decatur, Georgia, United States
UNM Research Program Psychedelic TherapiesRecruiting
Albuquerque, New Mexico, United States
Summit Headlands LLCRecruiting
Portland, Oregon, United States
Austin Clinical Trial PartnersRecruiting
Austin, Texas, United States
Aim Trials, LLCRecruiting
Plano, Texas, United States
Cedar Clinical ResearchRecruiting
Draper, Utah, United States
Inner Space State StreetRecruiting
Orem, Utah, United States
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder · TrialPath